3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
2
Phase 1/2
2
Status
Recruiting
4
Unknown
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Large B-Cell, Diffuse
2
Interventions
Cisplatin
130
Radiotherapy
94
Carboplatin
85
Paclitaxel
78
Fluorouracil
78
Cyclophosphamide
77
Gemcitabine
72
Capecitabine
66
Docetaxel
65
Doxorubicin
60
Oxaliplatin
59
Etoposide
57
Leucovorin
49
Vincristine
47
Chemotherapy, Adjuvant
42
Cytarabine
38
Dexamethasone
35
Drug Therapy
33
Bevacizumab
30
Epirubicin
29
Neoadjuvant Therapy
28
Pemetrexed
27
Tamoxifen
25
Prednisone
24
Irinotecan
24
Rituximab
21
Methotrexate
21
Radiotherapy, Intensity-Modulated
19
apatinib
18
Vinorelbine
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Unknown
×
orelabrutinib
×
Clear all
NCT05234684
2024-02-07
BELIEVE-01
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Unknown
150 enrolled
NCT05351346
2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3
Unknown
1,100 enrolled